JPWO2021216810A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216810A5 JPWO2021216810A5 JP2022563136A JP2022563136A JPWO2021216810A5 JP WO2021216810 A5 JPWO2021216810 A5 JP WO2021216810A5 JP 2022563136 A JP2022563136 A JP 2022563136A JP 2022563136 A JP2022563136 A JP 2022563136A JP WO2021216810 A5 JPWO2021216810 A5 JP WO2021216810A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 45
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 20
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims 17
- 102100021596 Interleukin-31 Human genes 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 11
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 6
- 229960002885 histidine Drugs 0.000 claims 6
- 241000283073 Equus caballus Species 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 241000282465 Canis Species 0.000 claims 3
- 241000282324 Felis Species 0.000 claims 3
- 241000282326 Felis catus Species 0.000 claims 3
- 238000012575 bio-layer interferometry Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- -1 CD11α Proteins 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 238000003119 immunoblot Methods 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 230000009131 signaling function Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 claims 1
- 101001044883 Homo sapiens Interleukin-22 receptor subunit alpha-1 Proteins 0.000 claims 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 claims 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010041012 Integrin alpha4 Proteins 0.000 claims 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 101710181613 Interleukin-31 Proteins 0.000 claims 1
- 108010067003 Interleukin-33 Proteins 0.000 claims 1
- 102000017761 Interleukin-33 Human genes 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 102000045345 human IL31 Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960002668 sodium chloride Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Claims (28)
(i)配列番号8または配列番号63のアミノ酸配列を含むCDR-L1;(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:63;
(ii)配列番号9のアミノ酸配列を含むCDR-L2;および(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9; and
(iii)配列番号10のアミノ酸配列を含むCDR-L3、(iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10;
を含む軽鎖、a light chain comprising
(b)以下、(b) Hereinafter,
(i)配列番号1のアミノ酸配列を含むCDR-H1;(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;
(ii)配列番号2、62、89または87のアミノ酸配列を含むCDR-H2;および(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 62, 89, or 87; and
(iii)配列番号3のアミノ酸配列を含むCDR-H3、(iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;
を含む重鎖、a heavy chain comprising
を含む、抗体。An antibody comprising:
(i)配列番号1のアミノ酸配列を含むCDR-H1;(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1;
(ii)配列番号2、62、89または87のアミノ酸配列を含むCDR-H2;および(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, 62, 89, or 87; and
(iii)配列番号3のアミノ酸配列を含むCDR-H3、(iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;
を含む重鎖、ならびにand a heavy chain comprising
(b)以下、(b) Hereinafter,
(i)配列番号8または配列番号63のアミノ酸配列を含むCDR-L1;(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:63;
(ii)配列番号9のアミノ酸配列を含むCDR-L2;および(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9; and
(iii)配列番号10のアミノ酸配列を含むCDR-L3、(iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10;
を含む軽鎖、a light chain comprising
を含む、抗体。An antibody comprising:
a)配列番号90の23位に対応する位置にチロシンまたはフェニルアラニン、
b)配列番号90の82位に対応する位置にチロシン、
c)配列番号90の82位に対応する位置にチロシンおよび207位に対応する位置にヒスチジン、
d)配列番号90の82位に対応する位置にチロシンおよび207位に対応する位置にチロシン、
e)配列番号90の207位に対応する位置にチロシン、
f)配列番号90の82位に対応する位置にチロシンおよび207位に対応する位置にヒスチジン、
g)配列番号90の82位に対応する位置にチロシンおよび207位に対応する位置にチロシン、または
h)配列番号90の207位に対応する位置にチロシン
を含む、請求項5または6に記載の抗体。 The variant IgG Fc polypeptide comprises
a) a tyrosine or phenylalanine at the position corresponding to position 23 of SEQ ID NO:90;
b) a tyrosine at a position corresponding to position 82 of SEQ ID NO:90;
c) a tyrosine at a position corresponding to position 82 and a histidine at a position corresponding to position 207 of SEQ ID NO:90;
d) a tyrosine at a position corresponding to position 82 and a tyrosine at a position corresponding to position 207 of SEQ ID NO:90;
e) a tyrosine at a position corresponding to position 207 of SEQ ID NO:90;
f) a tyrosine at a position corresponding to position 82 and a histidine at a position corresponding to position 207 of SEQ ID NO:90;
90。 The antibody of claim 5 or 6 , comprising: g) a tyrosine at the position corresponding to position 82 and a tyrosine at the position corresponding to position 207 of SEQ ID NO: 90; or h) a tyrosine at the position corresponding to position 207 of SEQ ID NO: 90.
a)配列番号90の23位にチロシンまたはフェニルアラニン、
b)配列番号90の82位にチロシン、
c)配列番号90の82位にチロシンおよび207位にヒスチジン、
d)配列番号90の82位にチロシンおよび207位にチロシン、
e)配列番号90の207位にチロシン、
f)配列番号90の82位にチロシンおよび207位にヒスチジン、
g)配列番号90の82位にチロシンおよび207位にチロシン;または
h)配列番号90の207位にチロシン
を含む、請求項5~7のいずれか一項に記載の抗体。 The variant IgG Fc polypeptide comprises
a) a tyrosine or phenylalanine at position 23 of SEQ ID NO:90;
b) a tyrosine at position 82 of SEQ ID NO:90;
c) a tyrosine at position 82 and a histidine at position 207 of SEQ ID NO:90;
d) a tyrosine at position 82 and a tyrosine at position 207 of SEQ ID NO:90;
e) a tyrosine at position 207 of SEQ ID NO:90;
f) a tyrosine at position 82 and a histidine at position 207 of SEQ ID NO:90;
8. The antibody of claim 5 , comprising: g) a tyrosine at position 82 and a tyrosine at position 207 of SEQ ID NO:90; or h) a tyrosine at position 207 of SEQ ID NO:90.
b)配列番号111、配列番号112、配列番号113、配列番号125、配列番号126または配列番号127の重鎖アミノ酸配列、
c)配列番号114、配列番号115または配列番号116の重鎖アミノ酸配列、
d)配列番号117、配列番号118または配列番号119の重鎖アミノ酸配列、または
e)配列番号120、配列番号121または配列番号122の重鎖アミノ酸配列
を含む、請求項1~8のいずれか一項に記載の抗体。 a) the heavy chain amino acid sequence of SEQ ID NO: 108, SEQ ID NO: 109 or SEQ ID NO: 110;
b) the heavy chain amino acid sequence of SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:125, SEQ ID NO:126 or SEQ ID NO:127;
c) the heavy chain amino acid sequence of SEQ ID NO: 114, SEQ ID NO: 115 or SEQ ID NO: 116;
d) the heavy chain amino acid sequence of SEQ ID NO:117, SEQ ID NO:118 or SEQ ID NO: 119 ; or e) the heavy chain amino acid sequence of SEQ ID NO:120, SEQ ID NO:121 or SEQ ID NO:122.
b)(i)配列番号21の軽鎖アミノ酸配列;(ii)配列番号111、配列番号112、配列番号113、配列番号125、配列番号126または配列番号127の重鎖アミノ酸配列;または(iii)(i)のような軽鎖アミノ酸配列および(ii)のような重鎖アミノ酸配列;または
c)(i)配列番号37の軽鎖アミノ酸配列;(ii)配列番号114、配列番号115または配列番号116の重鎖アミノ酸配列;または(iii)(i)のような軽鎖アミノ酸配列および(ii)のような重鎖アミノ酸配列;または
d)(i)配列番号38の軽鎖アミノ酸配列;(ii)配列番号117、配列番号118、配列番号119の重鎖アミノ酸配列;または(iii)(i)のような軽鎖アミノ酸配列および(ii)のような重鎖アミノ酸配列;または
e)(i)配列番号39の軽鎖アミノ酸配列;(ii)配列番号120、配列番号121または配列番号122の重鎖アミノ酸配列;または(iii)(i)のような軽鎖アミノ酸配列および(ii)のような重鎖アミノ酸配列
を含む、請求項1~9のいずれか一項に記載の抗体。 a) (i) a light chain amino acid sequence of SEQ ID NO:26; (ii) a heavy chain amino acid sequence of SEQ ID NO:108, SEQ ID NO:109 or SEQ ID NO:110; or (iii) a light chain amino acid sequence as in (i) and a heavy chain amino acid sequence as in (ii); or b) (i) a light chain amino acid sequence of SEQ ID NO:21; (ii) a heavy chain amino acid sequence of SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:125, SEQ ID NO:126 or SEQ ID NO:127; or (iii) a light chain amino acid sequence as in (i) and a heavy chain amino acid sequence as in (ii); or
c) (i) a light chain amino acid sequence of SEQ ID NO: 37; (ii) a heavy chain amino acid sequence of SEQ ID NO: 114, SEQ ID NO: 115 or SEQ ID NO: 116; or (iii) a light chain amino acid sequence such as (i) and a heavy chain amino acid sequence such as (ii); or
d) (i) a light chain amino acid sequence of SEQ ID NO: 38; (ii) a heavy chain amino acid sequence of SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119; or (iii) a light chain amino acid sequence such as (i) and a heavy chain amino acid sequence such as (ii); or e) (i) a light chain amino acid sequence of SEQ ID NO: 39; (ii) a heavy chain amino acid sequence of SEQ ID NO: 120, SEQ ID NO: 121 or SEQ ID NO: 122 ; or (iii) a light chain amino acid sequence such as (i) and a heavy chain amino acid sequence such as (ii).
a)薬学的に許容される担体が、L-ヒスチジン、塩化ナトリウムおよびポリソルベート80を含み、薬学的組成物が、5.0~6.2のpH、好ましくはpH5.0から6.0、または5.3から5.7、または5.5のpHを有する、および/または
b)薬学的組成物が、5mM~100mM、10mM~50mM、20mM~30mM、10~30mM、または20mMのL-ヒスチジン濃度を有する、および/または
c)薬学的組成物が、80~200mM、100~175mM、120~150mM、または140mMの塩化ナトリウム濃度を有する、および/または
d)薬学的組成物が、0.005mg/mL~0.5mg/mL、0.01mg/mL~0.1mg/mL、または0.05mg/mLのポリソルベート80濃度を有する、および/または
e)薬学的に許容される担体が、少なくとも一種類の糖を含む、および/または
f)薬学的組成物が、0.5%~20%、1%~10%、1%~5%または1%~3%の糖濃度を有する、および/または
g)薬学的に許容される担体が、スクロース、トレハロース、D-マンニトール、マルトースおよび/またはソルビトールを含む、および/または
h)薬学的組成物が、抗菌剤を含む、および/または
i)薬学的組成物が、m-クレゾールまたはメチルパラベンを含む、および/または
j)薬学的組成物が、0.2%のm-クレゾールおよび/または0.9%のメチルパラベンを含む、
薬学的組成物。 A pharmaceutical composition comprising the antibody according to any one of claims 1 to 12 and a pharma- ceutically acceptable carrier ;
a) the pharma- ceutically acceptable carrier comprises L-histidine, sodium chloride and polysorbate 80, and the pharmaceutical composition has a pH of 5.0 to 6.2, preferably pH 5.0 to 6.0, or 5.3 to 5.7, or 5.5; and/or
b) the pharmaceutical composition has an L-histidine concentration of 5 mM to 100 mM, 10 mM to 50 mM, 20 mM to 30 mM, 10 to 30 mM, or 20 mM; and/or
c) the pharmaceutical composition has a sodium chloride concentration of 80-200 mM, 100-175 mM, 120-150 mM, or 140 mM; and/or
d) the pharmaceutical composition has a polysorbate 80 concentration of 0.005 mg/mL to 0.5 mg/mL, 0.01 mg/mL to 0.1 mg/mL, or 0.05 mg/mL; and/or
e) the pharma- ceutically acceptable carrier comprises at least one sugar; and/or
f) the pharmaceutical composition has a sugar concentration of 0.5% to 20%, 1% to 10%, 1% to 5% or 1% to 3%; and/or
g) the pharma- ceutically acceptable carrier comprises sucrose, trehalose, D-mannitol, maltose and/or sorbitol; and/or
h) the pharmaceutical composition comprises an antibacterial agent, and/or
i) the pharmaceutical composition comprises m-cresol or methylparaben, and/or
j) the pharmaceutical composition comprises 0.2% m-cresol and/or 0.9% methylparaben;
Pharmaceutical compositions.
A method for detecting IL31 in a sample from a companion animal species, comprising contacting the sample with an antibody according to any one of claims 1 to 12 or a pharmaceutical composition according to claim 16 or 17 under conditions allowing binding of the antibody to IL31 and detecting whether a complex is formed between the antibody and IL31 in the sample ; the sample may be a biological sample obtained from a dog, a cat or a horse .
(i)イムノブロット解析および/またはバイオレイヤー干渉法によって決定される、ネコIL31またはウマIL31に結合する;(i) binds to feline IL31 or equine IL31 as determined by immunoblot analysis and/or biolayer interferometry;
(ii)イヌIL31への結合においてモノクローナルM14抗体と競合する;(ii) competes with monoclonal M14 antibody for binding to canine IL31;
(iii)ネコIL31への結合においてモノクローナルM14抗体と競合する;および/または(iii) competes with monoclonal M14 antibody for binding to feline IL31; and/or
(iv)イムノブロット解析および/またはバイオレイヤー干渉法によって決定される、ヒトIL31に結合しない、(iv) does not bind to human IL31 as determined by immunoblot analysis and/or biolayer interferometry;
請求項1~12、21~26のいずれか一項に記載の抗体。An antibody described in any one of claims 1 to 12 and 21 to 26.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063014033P | 2020-04-22 | 2020-04-22 | |
US63/014,033 | 2020-04-22 | ||
US202063014549P | 2020-04-23 | 2020-04-23 | |
US63/014,549 | 2020-04-23 | ||
PCT/US2021/028548 WO2021216810A1 (en) | 2020-04-22 | 2021-04-22 | Long-acting anti-il31 antibodies for veterinary use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023524643A JP2023524643A (en) | 2023-06-13 |
JPWO2021216810A5 true JPWO2021216810A5 (en) | 2024-05-02 |
Family
ID=78269992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022563136A Pending JP2023524643A (en) | 2020-04-22 | 2021-04-22 | Long-acting anti-IL31 antibodies for veterinary use |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230312702A1 (en) |
EP (1) | EP4138914A4 (en) |
JP (1) | JP2023524643A (en) |
KR (1) | KR20230005875A (en) |
CN (1) | CN115666644A (en) |
AU (1) | AU2021258198A1 (en) |
BR (1) | BR112022021216A2 (en) |
CA (1) | CA3173864A1 (en) |
MX (1) | MX2022013147A (en) |
WO (1) | WO2021216810A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107488228A (en) * | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | The antigen binding molecules combined repeatedly with the antigen of multiple molecules |
CN110114369A (en) * | 2016-10-17 | 2019-08-09 | 威隆股份公司 | The antibody constant region of modification |
WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
CN112020511A (en) * | 2018-03-16 | 2020-12-01 | 硕腾服务有限责任公司 | Interleukin-31 monoclonal antibodies for veterinary use |
KR20210110563A (en) * | 2018-10-18 | 2021-09-08 | 킨드레드 바이오사이언시스, 인코포레이티드 | FC variants with altered binding to the neonatal FC receptor (FCRN) for veterinary use |
EP3906259A2 (en) * | 2019-01-03 | 2021-11-10 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
WO2021188631A1 (en) * | 2020-03-18 | 2021-09-23 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
-
2021
- 2021-04-22 AU AU2021258198A patent/AU2021258198A1/en active Pending
- 2021-04-22 BR BR112022021216A patent/BR112022021216A2/en unknown
- 2021-04-22 US US17/996,557 patent/US20230312702A1/en active Pending
- 2021-04-22 EP EP21792891.0A patent/EP4138914A4/en active Pending
- 2021-04-22 WO PCT/US2021/028548 patent/WO2021216810A1/en unknown
- 2021-04-22 JP JP2022563136A patent/JP2023524643A/en active Pending
- 2021-04-22 KR KR1020227039975A patent/KR20230005875A/en active Search and Examination
- 2021-04-22 CA CA3173864A patent/CA3173864A1/en active Pending
- 2021-04-22 CN CN202180036332.3A patent/CN115666644A/en active Pending
- 2021-04-22 MX MX2022013147A patent/MX2022013147A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11697683B2 (en) | Anti-IL31 antibodies for veterinary use | |
JP5738294B2 (en) | Anti-VEGF monoclonal antibody and pharmaceutical composition containing the antibody | |
CN104903352A (en) | Multivalent binding protein compositions | |
CN110945026A (en) | Heavy chain-only anti-BCMA antibodies | |
WO2018156367A1 (en) | Anti-il31 antibodies for veterinary use | |
US20220049002A1 (en) | Anti-IL4 Receptor Antibodies for Veterinary Use | |
CA3169301A1 (en) | Anti-il4 receptor antibodies for veterinary use | |
CN114555121A (en) | Veterinary anti-IL 31 antibodies | |
US20220185879A1 (en) | IL17A Antibodies and Antagonists for Veterinary Use | |
US20230312702A1 (en) | Long-acting anti-il31 antibodies for veterinary use | |
JPWO2021216810A5 (en) | ||
RU2795485C2 (en) | Anti-il31 antibodies for veterinary use | |
CN112262213A (en) | Novel anti-PAD 2 antibodies | |
JPWO2021041972A5 (en) |